Abbvie Inc. · NYSE:ABBV
Abbvie — J.P. Morgan Healthcare Conference 2017
18 slides from Abbvie's conference presentation, Jan 11, 2017
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Richard Gonzalez Chief Executive Officer January 11, 2017 J.P. Morgan Healthcare Conference | January 11, 2017 |© 2017 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, gen
Slide 3: AbbVie Represents a Unique Investment Opportunity
AbbVie Represents a Unique Investment Opportunity Industry-leading growth, supported by a portfolio of leading brands in attractive and sustainable markets Track record of strong execution, consistently Impressive pipeline of late-stage, de-risked assets with potential to meeting or exceeding drive
Slide 4: Outstanding Track Record of Execution and Top-Tier Growth Prospects
Outstanding Track Record of Execution and Top-Tier Growth Prospects Low Double-Digit 13%-15% Adjusted Net Revenues Operational Adjusted EPS ($) Adjusted EPS Revenue Growth Growth ($BN) Approaching $4.81 $26BN Midpoint $22.8 $4.29 $18.8 $19.9 $3.32 > 12% $3.14 12.1% 14.8% 29.2% 12.1% 5.8% 5.7% 29.2%
Slide 5: AbbVie: An Innovation-Driven, Patient-Focused, Specialty Biopharmaceutical Company
AbbVie: An Innovation-Driven, Patient-Focused, Specialty Biopharmaceutical Company Oncology >$90BN Market Building Strong Leadership in Blood Cancers with IMBRUVICA & VENCLEXTA Building a Strong Presence in Immunology Solid Tumors with Stemcentrx and Other Virology $50BN Market Ongoing Efforts Stron
Slide 6: Building Sustainable Leadership Positions in Specialty Markets
Building Sustainable Leadership Positions in Specialty Markets Immunology Oncology Strong leadership position with Humira Building a sustainable leadership position in hematologic malignancies • Robust growth driven by continued bio-penetration; sustained leadership • Imbruvica and Venclexta well-po
Slide 7: Building Sustainable Leadership Positions in Specialty Markets
Building Sustainable Leadership Positions in Specialty Markets Neuroscience Virology Focused Investments Providing novel and effective Advancing our next generation Focused investments in other areas treatments for neurodegenerative HCV cure that complement our core strengths disorders • Highly effe
Slide 8: Immunology: Comprehensive Strategy to Maintain Strong Leadership Position
Immunology: Comprehensive Strategy to Maintain Strong Leadership Position Development Programs Focused on Re-defining Standard of Care Across Immune-Mediated Diseases Promising Early-Stage Differentiated Late-Stage Immunology Assets Programs Innovative Biologics Risankizumab ABT-494 & Small-Molecule
Slide 9: Building a Significant and Sustainable Leadership Position in Hematologic Malignancies Market
Building a Significant and Sustainable Leadership Position in Sizable and Growing Hematologic Malignancies Market Hematologic Malignancies, 2015 Global Hematologic Malignancies US+EU5 Prevalence(1) (000’s) Market Value Abbvie portfolio has potential to NHL2 address ~65% ~$50B 488 | 42% of market CLL
Slide 10: Building a Market Leadership Position in Hematologic Malignancies
Building a Market Leadership Position in Hematologic Malignancies Enable BTK and Bcl-2 inhibitors to become foundation Launched: 2013 1 therapies in CLL and other hematological malignancies First-in-class BTK inhibitor Transform the therapeutic approach, allowing patients Four FDA Breakthrough T
Slide 11: Establishing a Foundation in Solid Tumors
Establishing a Foundation in Solid Tumors Highly attractive foundational platform for solid tumors, utilizing cancer stem cell biology • Lead asset, Rova-T, represents a compelling growth platform; Potential for up to $5BN in peak-year sales 2018 Achieve fast-to-market in relapsed/refractory SCLC 20
Slide 12: Near-Term Growth Assets are Significantly De-risked
Near-Term Growth Assets are Significantly De-risked 2017 Key Pipeline Milestones for Near-Term Growth Assets Imbruvica Venclexta Next-Gen HCV Elagolix Rova-T ABT-494 Risankizumab 2L+ MZL approval r/r CLL Ph3 data, filing* Pan-Genotypic Endometriosis 3L SCLC PsA Ph3 start Psoriasis Ph3 data 2L cGvHD
Slide 13: De-Risked Growth Assets Alone Position AbbVie for Substantial Growth Beyond 2020
De-Risked Growth Assets Alone Position AbbVie for Substantial Growth Beyond 2020 $25-30BN* Eight Key Near-Term Growth Assets Imbruvica On-market, in late-stage development for additional indications Venclexta On-market, in late-stage development >$18BN for additional indications Zinbryta On-market N
Slide 14: AbbVie Offers Both Compelling Growth and Strong Capital Allocation
AbbVie Offers Both Compelling Growth and Strong Capital Allocation • Track record of strong and growing dividend; increasing 2017 dividend by 12%, beginning with dividend payable in February 2017 • Continued commitment to returning cash to shareholders Dividend Increases Reflect Growth of 60% Since
Slide 15: Strategic Partnerships Accelerate Development
Strategic Partnerships Accelerate Development Co-Development/ R & D / Venture In-License/Other Co-Promotion Acquisition California Life Company Note: Slide represents select examples only J.P. Morgan Healthcare Conference | January 11, 2017 |© 2017 15
Slide 16: AbbVie: A Unique Investment Opportunity
AbbVie: A Unique Investment Opportunity Sustainable leadership in specialty markets with Portfolio compelling on-market therapies Pipeline De-risked, late-stage programs poised to deliver significant growth Capital Allocation Attractive return of capital Track Record History of strong execution A un
Slide 17: Appendix
Qobvie
Slide 18: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations Diluted earnings per share 2013 2014 2015 2016E As reported (GAAP) $2.56 $1.10 $3.13 $3.75 Adjusted for specified items: Acquisition related expenses 0.23 0.18 0.45 0.70 Separation costs 0.10 0.24 0.13 -- Acquired in-process R&D, milestones and other R&D expenses 0.2